Understanding the Market | LEE'S PHARM rose over 27% in the afternoon as the application for the new indication of Socazoli monoclonal antibody was approved. Institutions are focusing on the palliative care track
LEE'S PHARM's stock price rose over 27% in the afternoon, and as of the time of writing, it has increased by 20.9%, reaching HKD 2.43, with a trading volume of HKD 44.9021 million. The company's interim results show a revenue of HKD 695 million, a year-on-year increase of 5.5%. The new indication application for Socazolimab submitted by its subsidiary has been approved. Dongxing Securities pointed out that the quality of life for cancer patients is a key focus, and LEE'S PHARM's AZ003 can effectively control cancer pain, which is expected to become an investment focus in the future
According to Zhitong Finance APP, LEE'S PHARM (00950) rose over 27% in the afternoon, and as of the time of writing, it was up 20.9%, trading at HKD 2.43, with a transaction volume of HKD 44.9021 million.
In terms of news, LEE'S PHARM previously released its interim results, reporting revenue of HKD 695 million, an increase of 5.5% year-on-year, primarily driven by the robust sales performance of the group's product portfolio. The company's attributable net profit for the first half of 2025 was HKD 67.185 million, a year-on-year increase of 7.5%. Notably, LEE'S PHARM announced at the end of July that its subsidiary, Zhaoke Pharmaceuticals, received approval for the new indication marketing application of the anti-PD-L1 monoclonal antibody Socazolimab.
Additionally, Zhongtai Securities released a research report stating that in recent years, innovative therapies such as dual antibodies, ADCs, small molecule targeted drugs (TKIs), and cell therapies have gradually extended the overall survival (OS) of cancer patients. The quality of life (QoL) of patients with tumors is an important issue of concern in clinical practice, and few pharmaceutical companies have previously focused on targeted drug development. The "palliative care discipline" focuses on important issues such as cancer cachexia and breakthrough cancer pain. The firm pointed out that LEE'S PHARM's developed fentanyl aerosol inhaler AZ003 can effectively control breakthrough cancer pain, with its Phase II clinical results to be published at the 2024 ASCO. The firm believes that multiple major products will emerge in this field in the future, which investors should pay attention to
